Efficacy of subcutaneous lidocaine injection in venous insufficiency: a prospective, randomized, controlled study, and new treatment protocol

Abstract

[Purpose] The purpose of this study was to evaluate the efficacy of subcutaneous injection with lidocaine in patients with chronic venous insufficiency in the early stage. [Subjects and Methods] Patients (n=50) randomized to the treatment group received subcutaneous injections from a mixture of physiological saline sterile solution and lidocaine once a week to both legs below the knee for 5 sessions. Patients in the treatment group were also given ankle pumping exercises and compression stockings throughout the treatment. Patients randomized to the control group (n=50) received only ankle pumping exercises and compression stockings. Patients were evaluated using the visual analog scale (VAS) for pain and Chronic Venous Disease Quality of life Questionnaire (CIVIQ-20) for quality-of-life at months 1, 3, 6, at the end of month 12, and at the end of the injection treatment for 5 sessions. [Results] CIVIQ-20 and VAS results were significantly lower in the treatment group, than in the control group at months 1, 3 and 6. However, CIVIQ-20 and VAS results were not significantly different, compared with the pre-operative period at month 12. [Conclusion] We observed that 5-week subcutaneous lidocaine injection treatment was effective in patients who do not respond to oral medical treatment or in whom surgery is not considered.

Measuring the Quality of Life in Patients with Chronic Venous Disease before and Short Term after Surgical Treatment—A Comparison between Different Open Surgical Procedures

“…Particularly for CVD, CIVIQ-20 proved to be a useful instrument for QoL measurement. Previous studies also revealed that CIVIQ-20 questionnaire results could be correlated with clinical signs and symptoms related with CVD [ 25 ], and the score results improve after the treatment, being directly correlated with the clinical evolution [ 26 ].…”

Scalable and Sustainable Synthesis of Calcium Dobesilate via Integrated Five-Step Continuous-Flow Chemistry

“…Calcium dobesilate ( 1 ) is an orally administered angioprotective agent for reducing blood, plasma, and aqueous humor hyperviscosity and microvascular hyperpermeability. − Up to approximately 60% incidence in developed countries use 1 as the oral treatment for diabetic retinopathy, hemorrhoidal syndrome, and chronic venous insufficiency in the lower limbs (pain, cramps, paresthesia, edema, and stasis dermatosis). − After being prescribed worldwide for many years, possible conferring benefits have been discovered including potential anticancer and antiviral effects. − Additionally, recent investigations have shown that 1 is an effective therapy for COVID-19 patients because its capacity to inhibit several signaling pathways can implicate COVID-19 pathophysiology. , …”